Next Article in Journal
An Overview of the Potential Therapeutic Applications of Essential Oils
Next Article in Special Issue
Highlights on Steroidal Arylidene Derivatives as a Source of Pharmacologically Active Compounds: A Review
Previous Article in Journal
The Structures, Molecular Orbital Properties and Vibrational Spectra of the Homo- and Heterodimers of Sulphur Dioxide and Ozone. An Ab Initio Study
Review

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules

1
KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa
2
School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa
3
Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain
4
CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Diego Muñoz-Torrero
Received: 9 January 2021 / Revised: 22 January 2021 / Accepted: 22 January 2021 / Published: 25 January 2021
(This article belongs to the Special Issue Molecules Medicinal Chemistry Reviews 2021)
Although the pharmaceutical industry will remember 2020 as the year of COVID-19, it is important to highlight that this year has been the second-best—together with 1996—in terms of the number of drugs accepted by the US Food and Drug Administration (FDA). Each of these two years witnessed the authorization of 53 drugs—a number surpassed only in 2018 with 59 pharmaceutical agents. The 53 approvals in 2020 are divided between 40 new chemical entities and 13 biologic drugs (biologics). Of note, ten monoclonal antibodies, two antibody–drug conjugates, three peptides, and two oligonucleotides have been approved in 2020. Close inspection of the so-called small molecules reveals the significant presence of fluorine atoms and/or nitrogen aromatic heterocycles. This report analyzes the 53 new drugs of the 2020 harvest from a strictly chemical perspective, as it did for those authorized in the previous four years. On the basis of chemical structure alone, the drugs that received approval in 2020 are classified as the following: biologics (antibodies, antibody-drug conjugates, and proteins); TIDES (peptide and oligonucleotides); natural products; fluorine-containing molecules; nitrogen aromatic heterocycles; and other small molecules. View Full-Text
Keywords: antibodies; antibody–drug conjugate; API; biologics; CBER; CDER; chemical entities; COVID-19; drug discovery; fluorine-based drugs; natural products; nitrogen aromatic heterocycles; oligonucleotides; peptides; TIDES; small molecules antibodies; antibody–drug conjugate; API; biologics; CBER; CDER; chemical entities; COVID-19; drug discovery; fluorine-based drugs; natural products; nitrogen aromatic heterocycles; oligonucleotides; peptides; TIDES; small molecules
Show Figures

Figure 1

MDPI and ACS Style

de la Torre, B.G.; Albericio, F. The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules 2021, 26, 627. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26030627

AMA Style

de la Torre BG, Albericio F. The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2021; 26(3):627. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26030627

Chicago/Turabian Style

de la Torre, Beatriz G., and Fernando Albericio. 2021. "The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules" Molecules 26, no. 3: 627. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26030627

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop